Use of PSMA PET/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer
Details
Publication Year 2020-06-24, Volume 16, Issue #43, Page e2003612
Journal Title
BJU International
Publication Type
Journal Article
Abstract
Prostate-specific membrane antigen (PSMA) PET/CT imaging is increasingly being utilised in clinical practice, demonstrating greater sensitivity in the detection of metastatic prostate cancer (mPC) compared to conventional imaging [1]. Prior studies have primarily focussed on its use following biochemical recurrence to detect oligometastatic disease potentially amenable to salvage therapies [2-4]. However, the role of PSMA PET/CT in assessing treatment response remains unclear. Standardised criteria for metabolic response have not been established, particularly to account for whole body tumour burden and the effects of systemic therapies on PSMA expression.
Publisher
Wiley
WEHI Research Division(s)
Personalised Oncology
PubMed ID
32579772
Publisher's Version
https://doi.org/10.1111/bju.15151
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2020-07-02 01:44:20
Last Modified: 2021-08-17 11:25:20
An error has occurred. This application may no longer respond until reloaded. Reload 🗙